Profile and outcomes of critically ill children in a lower middle-income country

Muhammad Irfan Habib1, Khalid Mehmood A Khan2

  • 1Department of Clinical, Child Life Foundation, Karachi, Pakistan.

Insights

Critically ill children, especially neonates, represent 8% of paediatric emergency visits and have a 13% mortality rate. Malnutrition is prevalent in this vulnerable group.

Area of Science:

  • Pediatric Emergency Medicine
  • Critical Care Pediatrics
  • Global Health

Background:

  • Critically ill children require immediate life-saving interventions.
  • Understanding their clinical profile and outcomes is crucial for resource allocation in lower-middle-income countries.

Purpose of the Study:

  • To determine the clinical profile and outcomes of critically ill children presenting to a pediatric emergency department (ED) in a lower-middle-income country.
  • To identify key demographic variables, presenting complaints, interventions, and outcomes for high-acuity pediatric patients.

Main Methods:

  • Retrospective analysis of children (<14 years) presenting to the National Institute of Child Health, Karachi, from January to December 2014.
  • Inclusion criteria: Emergency Severity Index acuity level 1 (requiring immediate life-saving interventions).
  • Data collected included demographics, presenting complaints, interventions, and ED outcomes.

Main Results:

  • Level 1 patients constituted 8% (13,551/172,162) of total ED visits.
  • Neonates (0-28 days) comprised 48% of level 1 children and 63% of all deaths.
  • Common complaints included respiratory and gastrointestinal symptoms; 64% of non-neonates were malnourished.

Conclusions:

  • High-acuity pediatric patients, particularly neonates, represent a significant burden on ED resources and have a high mortality rate.
  • Malnutrition is a common comorbidity in critically ill children presenting to the ED.
  • Effective interventions and resource management are vital for improving outcomes in this population.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
377
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
381
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
977